Vanguard Group Inc Bei Gene, Ltd. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $131,536 - $201,835	998 Added 1.18%	85,508 $11.5 Million
Q2 2022 Aug 12, 2022	BUY	$121.11 - $216.05 $92,649 - $165,278	765 Added 0.91%	84,510 $13.7 Million
Q1 2022 May 13, 2022	BUY	$146.52 - $269.56 $621,977 - $1.14 Million	4,245 Added 5.34%	83,745 $15.8 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $1.46 Million - $2.28 Million	-5,861 Reduced 6.87%	79,500 $21.5 Million
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $178,214 - $287,841	714 Added 0.84%	85,361 $31 Million
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $24.8 Million - $31.1 Million	84,647 New	84,647 $29.1 Million

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.